Respiratory viruses are a major cause of mortality worldwide, with an estimated 2.7 million deaths in 2015 ([@bib0015]). In France, they cause several thousands of deaths every year during the colder months ([@bib0030]). Since January 2020, the SARS-CoV-2 outbreak has generated much fear and countermeasures to stem the spread of this respiratory virus. This has largely been fueled by the tremendously extensive reporting of Covid-19-associated deaths. As of 31 March 2020, 770,520 people have been found infected worldwide, of whom 36,942 (4.8%) died. Five countries (Italy, Spain, China, USA and France) have been affected by 77% of these deaths (<https://coronavirus.jhu.edu/map.html>). France identified 3,024 deaths for 44,450 infections (6.8%). The University Hospital Institute Méditerranée Infection performs, with in-house tools, a real-time surveillance of all infections in public hospitals in Marseille, Southeastern France ([@bib0005], [@bib0035]). This surveillance allows weekly analysis of the numbers of each type of clinical sample received and any pathogen diagnosed at the laboratory, including respiratory samples and viruses, and performing retrospective analyses that include the most recently available data. It also includes the count of the deaths associated with any diagnosed infection. This study compared the mortality associated with diagnoses of respiratory viruses during the colder months overlapping 2018--2019 and 2019--2020.

Testing of respiratory samples was performed using FTD Respiratory pathogens 21 (Fast Track Diagnosis, Luxembourg) or Biofire FilmArray Respiratory panel 2 plus (Biomérieux, France) assays. Between week 47 of 2018 and week 14 of 2019, 73 patients died after being diagnosed with respiratory viruses ([Table 1](#tbl0005){ref-type="table"} ). They represented 0.17% of the 42,851 patients hospitalized during this period and 6.3% of the 1,137 who died. Deaths occurred in 40 of the patients diagnosed with influenza A virus (1.7%), which was the respiratory virus associated with the highest number of deaths. In addition, deaths occurred in 19 of the patients diagnosed with rhinoviruses (1.5%), and in 13 of those diagnosed with respiratory syncytial virus (RSV) (1.1%). Respiratory samples had not been tested for coronaviruses and parainfluenza viruses in routine clinical practice, but all those retrospectively tested from patients who died in Marseille public hospitals were negative. In comparison, during the same period of winter 2019--2020 (between week 47 of 2019 and week 14 of 2020), 50 patients died after being diagnosed with a common respiratory virus. They represented 0.10% of the 49,043 patients hospitalized during this period and 4.5% of the 1,115 who died. They included seven of the patients diagnosed with influenza A virus (0.5%), three of those diagnosed with influenza B virus (0.2%), seven of those diagnosed with RSV (0.7%), and six, two and one of those diagnosed with human coronavirus-HKU1 (2.4%), NL63 (1.2%) and OC43 (0.8%), respectively ([Table 1](#tbl0005){ref-type="table"}). Additionally, since the 29 January 2020, 25,786 patients were tested for SARS-CoV-2 using a reverse transcription-PCR assay ([@bib0010]), and 3,587 infections were diagnosed positive (13.9%). Of these infected patients, 55 (1.5%) died; their median age was 82 years.Table 1Tests performed and positive for PCR detection of respiratory viruses, and associated deaths during the same colder months overlapping the years 2018--2019 and 2019--2020.Table 1VirusesTestsPositive patientsDeaths*P*[a](#tblfn0005){ref-type="table-fn"}2018--20192019--20202018--20192019--20202018--20192019--2020NumberNumberNumber*%*Number*%*Number%Number*%*Adenovirus11,92216,098475*4.0*448*2.8*2*0.4*4*0.9*Coronavirus HKU1--10,097----253*2.5*----6*2.4*Coronavirus NL63--10,097----173*1.7*----2*1.2*Coronavirus OC43--10,097----120*1.2*----1*0.8*Coronavirus E229--10,097----69*0.7*----0*0.0*SARS-CoV-2--42,242----3,587*8.5*----55*1.5*Enterovirus11,92216,098343*2.9*362*2.3*1*0.3*2*0.6*Influenza A virus11,92216,0982,293*19.2*1,554*9.7*40*1.7*7*0.5\<0.001*Influenza B virus11,92216,09815*0.1*1,261*7.8*0*0.0*3*0.2*Metapneumovirus11,92216,098346*2.9*472*2.9*0*0.0*5*1.1*Parainfluenza virus 1--10,097----7*0.1*----0*0.0*Parainfluenza virus 2--10,097----12*0.1*----0*0.0*Parainfluenza virus 3--10,097----11*0.1*----0*0.0*Parainfluenza virus 4--10,097----30*0.3*----0*0.0*Rhinovirus11,92216,0981,241*10.4*1,565*9.7*19*1.5*15*1.00.11*Syncytial respiratory virus11,92216,0981,146*9.6*1,044*6.5*13*1.1*7*0.70.18*[^2]

Thus, a total of 105 patients died after being diagnosed with a respiratory virus during the colder months of 2019--2020 until week 14 of 2020 compared with 73 the year before during the same timeframe (+44%). However, the proportion of respiratory virus-associated deaths among hospitalized patients did not significantly differ in 2019--2020 and 2018--2019 (214 versus 170 per 100,000 hospitalized patients; *p* = 0.08, Yates-corrected Chi-square test). In contrast, it was significantly lower in 2019--2020 than in 2018--2019 for common respiratory viruses (102 versus 170 per 100,000 hospitalized patients; *p* = 0.003), which were associated with 33% fewer deaths in 2019--2020. This drop was essentially due to a significant decrease in influenza A virus-associated deaths (--84%; *p* \<0.001) and a decrease in RSV-associated deaths (-46%; *p* = 0.18)among patients diagnosed with these viruses. The drop in influenza-associated deaths could be partly explained by the predominance of A/H3N2 strains in 2018--2019 compared with the predominance of A/H1N1 and B strains in 2019--2020, as A/H3N2 strains were reported to be associated with a greater mortality in elderly people ([@bib0020], [@bib0025]). A 21% drop in the number of deaths in patients diagnosed with rhinovirus, and a reduction from 1.5% to 1% of the proportion of deaths among diagnosed patients (*p* = 0.11) was also observed in 2019--2020 compared with 2018--2019.

Overall, these findings put into perspective the death burden of SARS-CoV-2 infections in this geographical area. Thus, the number of SARS-CoV-2-associated deaths was similar to that of deaths associated with other viral respiratory infections between December 2019 and March 2020, and lower than that of deaths associated with viral respiratory infections between December 2018 and March 2019. In addition, no significant impact of SARS-CoV-2 infections was observed on the overall number of deaths (of any cause) among hospitalized people in Marseille public hospitals (1,115 deaths in 2019--2020 during the study period versus 1,137 in 2018--2019; [Figure 1](#fig0005){ref-type="fig"} a), or in the population of metropolitan France (175,384 deaths in 2019--2020 versus 173,923 in 2018--2019; [Figure 1](#fig0005){ref-type="fig"}b; <https://www.insee.fr/fr/statistiques/serie/000436394#Telechargement>). Further analyses might determine if this is related to containment or other changes related to the SARS-CoV-2 epidemics. The number of SARS-CoV-2-associated deaths will grow after the timeframe of the present study as a consequence of recent or new infections, but the peak of incidence of SARS-CoV-2 infections was reached at the end of March 2020 in Marseille public hospitals (<https://www.mediterranee-infection.com/covid-19/>) and in metropolitan France (<https://www.santepubliquefrance.fr/content/download/246357/2578114>).Figure 1Number of deaths of any cause per month in Marseille public hospitals (a) and in Metropolitan France (<https://www.insee.fr/fr/statistiques/serie/000436394#Telechargement>) (b).Periods of time analysed in the present study are indicated by the rectangles with a grey background.Figure 1
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